The Use of MiniMed780G System Is Associated With Stable Glycemic Control in People With Type 1 Diabetes Before, During, and After Ramadan: An Observational Study
Journal of Diabetes Research · 2025-01 · 2025 (1)
DOI: 10.1155/jdr/4144787 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Diabetes Research, online erschienen am 02.01.2025. Verfasst von Abdullah M Alguwaihes und 4 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Unit, Internal Medicine Department, College of Medicine, King Saud University, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Blood Glucose, Blood Glucose Self-Monitoring, Diabetes Mellitus, Type 1, Fasting. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
The study was aimed at assessing the role of the MiniMed780G system of glycemic control before, during, and after Ramadan among people with Type 1 diabetes (PwT1D).
Methods
This is a single‐center retrospective analysis of MiniMed780G system users aged 14 years and above whose glycemic profiles were collected from February 21 to May 20, 2023, which corresponds to the Hijri months of Sha’ban, Ramadan, and Shawwal 1444/1445. Data was collected, processed, and analyzed in the framework of the Medtronic Galaxy service of the One Hospital Clinical Service (OHCS) program in Dallah Hospital, Riyadh, Saudi Arabia. Data from 43 PwT1D (24 females, mean age 30 ± 11 years with 14 ± 8 years from diabetes onset) using the MiniMed780G system were collected.
Results
Overall, the 3‐month (Sha’ban, Ramadan, and Shawwal) mean sensor glucose (SG), time in range (TIR) (70–180 mg/dL), time below range (TBR) (54–69 mg/dL and < 54 mg/dL), time above range (TAR) (180–250 mg/dL and > 250 mg/dL), and glucose management indicator (GMI) showed no statistical differences within the three periods. No differences in insulin total daily dose have been detected, and no diabetic ketoacidosis (DKA) or severe hypoglycemia events occurred.
Conclusion
The use of the MiniMed780G system is safe with favorable glycemic outcomes across nonfasting and fasting months.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrinology Unit, Internal Medicine Department, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
- Diabetes Center, Dallah Hospital, Riyadh, Saudi Arabia.
- Internal Medicine, King Saud University Medical City, Riyadh, Saudi Arabia.
- University Diabetes Center, King Saud University Medical City, Riyadh, Saudi Arabia.
ORCID-Profile: Abdullah M Alguwaihes, Najla Alotaibi, Metib Alotaibi
Zitieren
APA
Alguwaihes, A. M., Alotaibi, N., Alotaibi, M., Masry, N., & Safarini, S. (2025). The Use of MiniMed780G System Is Associated With Stable Glycemic Control in People With Type 1 Diabetes Before, During, and After Ramadan: An Observational Study. Journal of Diabetes Research, 2025(1). https://doi.org/10.1155/jdr/4144787
Vancouver
Alguwaihes AM, Alotaibi N, Alotaibi M, Masry N, Safarini S. The Use of MiniMed780G System Is Associated With Stable Glycemic Control in People With Type 1 Diabetes Before, During, and After Ramadan: An Observational Study. Journal of Diabetes Research. 2025;2025(1). doi:10.1155/jdr/4144787
BibTeX
@article{Alguwaihes2025,
author = {Alguwaihes, Abdullah M and Alotaibi, Najla and Alotaibi, Metib and Masry, Naglaa and Safarini, Saher},
title = {The Use of MiniMed780G System Is Associated With Stable Glycemic Control in People With Type 1 Diabetes Before, During, and After Ramadan: An Observational Study},
journal = {Journal of Diabetes Research},
year = {2025},
volume = {2025},
number = {1},
doi = {10.1155/jdr/4144787}
}
EUVIMED